FIBROMYALGIA, DEPRESSION AND MYOFASCIAL TMD
纤维肌痛、抑郁症和肌筋膜 TMD
基本信息
- 批准号:2843420
- 负责人:
- 金额:$ 48.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-07-01 至 2003-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (taken from the application):
The well-established comorbidity of fibromyalgia (FMS) and major depression
(MDD) has motivated speculations about the direction of the relationship. Three
principal hypotheses to be tested here are: (l)that FMS is a variant of
depression; (2) that MDD in FMS sufferers is a reaction to FMS; and (3) that
high rates of MDD in FMS patients are an artifact of studying
treatment-seekers. The proposed study's first aim is to support one and refute
other hypotheses, by conducting a family study. Community women meeting
criteria for FMS (n= 120) will be stratified so that half (n=60) have a
lifetime history of MDD. Demographically-matched non-FMS controls (n= 120) from
the same sampling frame will also be stratified on MDD status. Direct
psychiatric interviews and physical examinations will be conducted with
probands and all their available adult first degree relatives. To support the
first hypothesis, familial MDD rates should be elevated in FMS probands, even
among probands with no personal depression histories; to support the second,
probands with FMS and MDD should have low familial depression rates, as their
depression should be more likely reactive to FMS; to support the last, familial
MDD should be elevated in probands with MDD histories themselves, regardless of
FMS status. A second aim, prompted by the comorbidity of FMS and myofascial
temporomandibular disorder (M/TMD), is test (1) whether M/TMD is a regional
manifestation of FMS or (2) whether M/TMD comorbid with FMS is different from
M/TMD expressed as a regional disorder. To accomplish this aim, we will first
reconfirm that FMS is familial, utilizing data gathered to satisfy the first
aim. Second, we will reconstitute the groups from Aim 1, according to both FMS
and M/TMD status. Rates of familial M/TMD in FMS and control probands, broken
down by proband M/TMD status, will be examined. If M/TMD is found in the family
of FMS probands, regardless of proband M/TMD status, this will support the
first hypothesis. If only FMS probands have familial M/TMD but M/TMD probands
do not, this will support the 2nd hypothesis and indicate that the two
disorders are provoked through different pathogenic processes.
描述(取自应用程序):
纤维肌痛(FMS)和重度抑郁症的明确共病
(MDD)引发了人们对这段关系走向的猜测。三
这里要检验的主要假设是:(1)FMS是一种变体,
抑郁症;(2)FMS患者的MDD是对FMS的反应;(3)
FMS患者中MDD的高发生率是研究
寻求治疗的人这项研究的第一个目的是支持一个观点,
其他假设,通过进行家庭研究。社区妇女会议
将对FMS标准(n= 120)进行分层,以便一半(n=60)具有
MDD的终身史。人口统计学匹配的非FMS对照组(n= 120),
同样的采样框架也将根据MDD状态进行分层。直接
将进行精神病面谈和身体检查,
先证者和他们所有的成年一级亲属。支持
第一个假设,家族性MDD率应在FMS先证者中升高,即使
在没有个人抑郁史的先证者中;为了支持第二个,
FMS和MDD的先证者应该有较低的家族性抑郁率,因为他们
抑郁症应该更容易对FMS反应;为了支持最后一个家族性的
MDD在有MDD病史的先证者中应该升高,无论
FMS状态。第二个目标,由FMS和肌筋膜的并发症引起,
颞下颌关节紊乱病(M/TMD),是测试(1)M/TMD是否是一个区域性
(2)M/TMD是否与FMS共病,
M/TMD表现为区域性疾病。为了实现这一目标,我们将首先
再次确认FMS是家族性的,利用收集的数据来满足第一个
瞄准其次,我们将根据两个FMS,
M/TMD状态。FMS和对照先证者中家族性M/TMD的发生率,
根据先证者M/TMD状态,将进行检查。如果在家族中发现M/TMD
的FMS先证者,无论先证者M/TMD状态如何,这将支持
第一个假设如果只有FMS先证者有家族性M/TMD,但M/TMD先证者
这将支持第二个假设,并表明两个
疾病是通过不同的致病过程引起的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KAREN G. RAPHAEL其他文献
KAREN G. RAPHAEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KAREN G. RAPHAEL', 18)}}的其他基金
Preliminary Safety Study of Botulinum Toxin for Treatment of Myofascial TMJD Pain
肉毒毒素治疗肌筋膜下颌关节疼痛的初步安全性研究
- 批准号:
9113560 - 财政年份:2014
- 资助金额:
$ 48.53万 - 项目类别:
Preliminary Safety Study of Botulinum Toxin for Treatment of Myofascial TMJD Pain
肉毒毒素治疗肌筋膜下颌关节疼痛的初步安全性研究
- 批准号:
9020301 - 财政年份:2014
- 资助金额:
$ 48.53万 - 项目类别:
Randomized controlled clinical trial of botulinum toxin for myofascial TMJD pain
肉毒杆菌毒素治疗肌筋膜 TMJD 疼痛的随机对照临床试验
- 批准号:
8384755 - 财政年份:2012
- 资助金额:
$ 48.53万 - 项目类别:
Sleep Bruxism and Central Sensitization in Myofascial Face Pain
睡眠磨牙症和肌筋膜面部疼痛的中枢敏化
- 批准号:
7323197 - 财政年份:2007
- 资助金额:
$ 48.53万 - 项目类别:
Sleep Bruxism and Central Sensitization in Myofascial Face Pain
睡眠磨牙症和肌筋膜面部疼痛的中枢敏化
- 批准号:
7905417 - 财政年份:2007
- 资助金额:
$ 48.53万 - 项目类别:
Sleep Bruxism and Central Sensitization in Myofascial Face Pain
睡眠磨牙症和肌筋膜面部疼痛的中枢敏化
- 批准号:
7870924 - 财政年份:2007
- 资助金额:
$ 48.53万 - 项目类别:
Sleep Bruxism and Central Sensitization in Myofascial Face Pain
睡眠磨牙症和肌筋膜面部疼痛的中枢敏化
- 批准号:
7907916 - 财政年份:2007
- 资助金额:
$ 48.53万 - 项目类别:
Sleep Bruxism and Central Sensitization in Myofascial Face Pain
睡眠磨牙症和肌筋膜面部疼痛的中枢敏化
- 批准号:
8122353 - 财政年份:2007
- 资助金额:
$ 48.53万 - 项目类别:
Sleep Bruxism and Central Sensitization in Myofascial Face Pain
睡眠磨牙症和肌筋膜面部疼痛的中枢敏化
- 批准号:
7482448 - 财政年份:2007
- 资助金额:
$ 48.53万 - 项目类别:
Sleep Bruxism and Central Sensitization in Myofascial Face Pain
睡眠磨牙症和肌筋膜面部疼痛的中枢敏化
- 批准号:
7663776 - 财政年份:2007
- 资助金额:
$ 48.53万 - 项目类别:
相似海外基金
睡眠時無呼吸症と睡眠時ブラキシズムのcomorbidityを成立させる病態生理機構の解明
阐明睡眠呼吸暂停和睡眠磨牙症并存的病理生理机制
- 批准号:
24K02631 - 财政年份:2024
- 资助金额:
$ 48.53万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
ARISTOTELES - Applying ARtificial Intelligence to Define clinical trajectorieS for personalized predicTiOn and early deTEctiOn of comorbidiTy and muLtimorbidiTy pattErnS
亚里士多德 - 应用人工智能定义临床轨迹,以实现个性化预测以及合并症和多发病模式的早期检测
- 批准号:
10103153 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
EU-Funded
Macrophage metabolism in diabetes and tuberculosis comorbidity
糖尿病和结核病合并症中的巨噬细胞代谢
- 批准号:
10645801 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
Resolving sources of heterogeneity and comorbidity in alcohol use disorder
解决酒精使用障碍的异质性和合并症的来源
- 批准号:
10783325 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
Involvement of dopamine signaling in chronic pain-induced negative affective state and nicotine use comorbidity
多巴胺信号传导参与慢性疼痛引起的负面情感状态和尼古丁使用合并症
- 批准号:
10662951 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
HIV-1 and Alzheimer’s disease: Comorbidity
HIV-1 和阿尔茨海默病:合并症
- 批准号:
10760712 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
Insulin-like Growth Factor-1 (IGF-1) signalling in immunometabolism of TB and TB-Diabetes comorbidity
胰岛素样生长因子-1 (IGF-1) 信号在结核病和结核病-糖尿病合并症免疫代谢中的作用
- 批准号:
10734113 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
Genetic Comorbidity of PTSD and Substance Use Disorders in Diverse Populations.
不同人群中 PTSD 和药物使用障碍的遗传共病。
- 批准号:
10658078 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
Closing the Comorbidity Gap for People Living with HIV : a Randomized Controlled Trial of Fostemsavir to Reduce Inflammaging
缩小艾滋病毒感染者的合并症差距:Fostemsavir 减少炎症的随机对照试验
- 批准号:
485532 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
Operating Grants
New insights into the development of metabolic dysfunction as a comorbidity in Crohn's disease.
关于代谢功能障碍作为克罗恩病合并症的发展的新见解。
- 批准号:
493720 - 财政年份:2023
- 资助金额:
$ 48.53万 - 项目类别:
Operating Grants